Snakebite envenoming from a global perspective: Towards an integrated approach

Toxicon

Volumn 56, Issue 7, 2010, Pages 1223-1235

  Gutiérrez, José María ^a   Williams, David ^b   Fan, Hui Wen ^c   Warrell, David A ^b,d  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c INSTITUTO BUTANTAN   (Brazil)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antivenom; Clinical trials; Community education; Disability; Envenoming; Neglected disease; Prevention; Quality control; Snakebite; Training health personnel; Transfer of technology

Indexed keywords

PLACEBO; SNAKE VENOM; VENOM ANTISERUM;

CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; EDUCATION PROGRAM; ENVENOMATION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; IMMUNIZATION; INCIDENCE; LOWEST INCOME GROUP; MEDICAL EDUCATION; MORTALITY; NONHUMAN; POLITICAL PARTICIPATION; POPULATION RESEARCH; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RURAL AREA; SNAKEBITE; TECHNOLOGY;

ANTIVENINS; DELIVERY OF HEALTH CARE, INTEGRATED; HEALTH SERVICES ACCESSIBILITY; HUMANS; INCIDENCE; QUALITY CONTROL; SNAKE BITES;

EID: 77951654154     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2009.11.020     Document Type: Review

References (71)

1. Abubakar S.B., Abubakar I.S., Habib A.G., Nasidi A., Durfa N., Yusuf P.O., Larnyang S., Garnvwa J., Sokomba E., Salako L., Laing G.D., Theakston R.D., Juszczak E., Alder N., Warrell D.A., For the Nigeria-UK EchiTab Study Group Pre-clinical and preliminary dose-finding and safety studies to identify candidate antivenoms for treatment of envenoming by saw-scaled or carpet vipers (Echis ocellatus) in northern Nigeria. Toxicon 2009 Oct 26, [Epub ahead of print].
2. Ariaratnam C.A., Thuraisingam V., Kularatne S.A., Sheriff M.H., Theakston R.D.G., de Silva A., Warrell D.A. Frequent and potentially fatal envenoming by hump-nosed pit vipers (Hypnale hypnale and H. nepa) in Sri Lanka: lack of effective antivenom. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:1120-1126.
3. Bon C. Serum therapy was discovered 100 years ago. Envenomings and Their Treatments 1996, 3-9. Fondation Marcel Mérieux, Lyon. C. Bon, M. Goyffon (Eds.).
4. Burnouf T., Terpstra F., Habib G., Seddik S. Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms. Biologicals 2007, 35:329-334.
5. Calvete J.J., Juárez P., Sanz L. Snake venomics. Strategy and applications. J. Mass Spectrom. 2007, 42:1405-1414.
6. Calvete J.J., Sanz L., Angulo Y., Lomonte B., Gutiérrez J.M. Venoms, venomics, antivenomics. FEBS Lett. 2009, 583:1736-1743.
7. Cardoso J.L.C., Fan H.W., França F.O.S., Jorge M.T., Leite R.P., Nishioka S.A., Avila A., Sano-Martins I.S., Tomy S.C., Santoro M.L., Chudzinski A.M., Castro S.C.B., Kamiguti A.S., Kelen E.M.A., Hirata M.H., Mirandola R.M.S., Theakston R.D.G., Warrell D.A. Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in São Paulo, Brazil. Q. J. Med. 1993, 86:315-325.
8. Cheng A.C., Winkel K.D. Snakebite and antivenoms in the Asia-Pacific: wokbaut wantaim, raka hebou (" walking together" ). Med. J. Aust. 2001, 175:648-651.
9. Chippaux J.P. Snake-bites: appraisal of the global situation. Bull. World Health Organ. 1998, 76:515-524.
10. Chippaux J.P. The treatment of snake bites: analysis of requirements and assessment of therapeutic efficacy in tropical Africa. Perspectives in Molecular Toxinology 2002, 457-472. John Wiley, England. A. Ménez (Ed.).
11. Chippaux J.P., Williams V., White J. Snake venom variability: methods of study, results and interpretation. Toxicon 1991, 29:1279-1303.
12. 2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. Trans. R. Soc. Trop. Med. Hyg. 1998, 92:657-662.
13. 2 polyvalent equine antivenom for African snake bites in Benin. Am. J. Trop. Med. Hyg. 2007, 77:538-546.
14. Chotwiwatthanakun C., Pratanaphon R., Akesowan S., Sriprapat S., Ratanabanangkoon K. Production of potent polyvalent antivenom against three elapid venoms using a low dose, low volume, multi-site immunization protocol. Toxicon 2001, 39:1487-1494.
15. de Oliveira R.C., Wen F.H., Sifuentes D.N. Epidemiologia dos acidentes por animais peçonhentos. Animais Peçonhentos no Brasil. Biologia, Clínica e Terapêutica dos Acidentes 2009, 6-21. Sarvier, Sao Paulo. J.L.C. Cardoso, F.O.S. França, F.H. Wen, C.M.S. Málaque, V. Haddad (Eds.).
16. Fox S., Rathuwithana A.C., Kasturiratne A., Lalloo D.G., de Silva H.J. Underestimation of snakebite mortality by hospital statistics in the Monaragala district of Sri Lanka. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:693-695.
17. Gehan E.A. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chronic Dis. 1961, 13:346-353.
18. 2 antivenoms. An example: new polyvalent European viper antivenom (equine). Envenomings and Their Treatments 1996, 161-172. Fondation Marcel Mérieux, Lyon. C. Bon, M. Goyffon (Eds.).
19. Gutiérrez J.M., León G. Snake antivenoms. Technological, clinical and public health issues. Animal Toxins: State of the Art. Perspectives in Health and Biotechnology 2009, 393-421. Editora UFMG, Belo Horizonte. M.E. de Lima, A.M.C. Pimenta, M.F. Martin-Euclairte, R.B. Zingali, H. Rochat (Eds.).
20. Gutiérrez J.M., Rojas G., Bogarín G., Lomonte B. Evaluation of the neutralizing ability of antivenoms for the treatment of snakebite envenoming in Central America. Envenomings and Their Treatments 1996, 223-231. Fondation Marcel Mérieux, Lyon. C. Bon, M. Goyffon (Eds.).
21. Gutiérrez J.M., Rojas E., Quesada L., León G., Núñez J., Laing G.D., Sasa M., Renjifo J.M., Nasidi A., Warrell D.A., Theakston R.D.G., Rojas G. Pan-African polyspecific antivenom produced by caprylic acid purification of horse IgG: an alternative to the antivenom crisis in Africa. Trans. R. Soc. Trop. Med. Hyg. 2005, 99:468-475.
22. Gutiérrez J.M., Theakston R.D.G., Warrell D.A. Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Med. 2006, 3:e412.
23. Gutiérrez J.M., Higashi H.G., Wen F.H., Burnouf T. Strengthening antivenom production in Central and South American public laboratories: report of a workshop. Toxicon 2007, 49:30-35.
24. Gutiérrez J.M., Lomonte B., León G., Rucavado A., Chaves F., Angulo Y. Trends in snakebite envenomation therapy: scientific, technological and public health considerations. Curr. Pharm. Des. 2007, 13:2935-2950.
25. Gutiérrez J.M., Wen F.H., Silvera C.L., Angulo Y. Stabillity, distibution and use of antivenoms for snakebite envenomation in Latin America: report of a workshop. Toxicon 2009, 53:625-630.
26. Gutiérrez J.M., Lomonte B., León G., Alape-Girón A., Flores-Díaz M., Sanz L., Angulo Y., Calvete J.J. Snake venomics and antivenomics: proteomic tools in the design and control of antivenoms for the treatment of snakebite envenoming. J. Proteomics 2009, 72:165-182.
27. Hati A.K., Mandal M., De M.K., Mukherjee H., Hati R.N. Epidemiology of snake bite in the district of Burdwan, West Bengal. J. Indian Med. Assoc. 1992, 90:145-147.
28. Hotez P.J., Molyneux D.H., Fenwick A., Ottensen E., Ehrlich-Sachs S., Sachs J.D. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med. 2006, 3:e102.
29. Hunt P. Neglected Diseases: A Human Rights Analysis 2007, World Health Organization, Geneva.
30. Instituto Clodomiro Picado Determinación de Actividades Tóxicas de Venenos de Serpientes y su Neutralización por Antivenenos. Manual de Métodos de Laboratorio 2008, Instituto Clodomiro Picado, San José, Costa Rica.
31. Jorge M.T., Cardoso J.L.C., Castro S.C.B., Ribeiro L.A., França F.O.S., Sbrogio de Almeida M.E., Kamiguti A.S., Sano-Martins I.S., Santoro M.L., Moncau J.E.C., Warrell D.A., Theakston R.D.G. A ramdomized 'blinded' comparison of two doses of antivenom in the treatment of Bothrops envenoming in São Paulo, Brazil. Trans. R. Soc. Trop. Med. Hyg. 1995, 89:111-114.
32. Kasturiratne A., Wickremasinghe A.R., de Silva N., Gunawardena N.K., Pathmeswaran A., Premaratna R., Savioli L., Lalloo D.G., da Silva H.J. The global burden of snakebite: a literature analysis and modeling based on regional estimates of envenoming and deaths. PLoS Med. 2008, 5:e218.
33. Kindhauser M. Communicable Diseases 2002: Global Defense Against the Infectious Disease Threat 2003, World Health Organization, Geneva, (WHO/CDS/2003.15).
34. Lalloo D.G., Theakston R.D.G. Snake antivenoms. J. Toxicol. Clin. Toxicol. 2003, 41:317-327.
35. Leynaud G.C., Reati G.J. Identificación de las zonas de riesgo ofídico en Córdoba, Argentina, mediante el programa SIGEpi. Rev. Panam. Salud Pública 2009, 26:64-69.
36. Lomonte B., Escolano J., Fernández J., Sanz L., Angulo Y., Gutiérrez J.M., Calvete J.J. Snake venomics and antivenomics of the arboreal neotropical pitvipers Bothriechis lateralis and Bothriechis schlegelii. J. Proteome Res. 2008, 7:2445-2457.
37. McGain F., Limbo A., Williams D., Didei G., Winkel K.D. Snake bite mortality at Port Moresby general hospital, Papua New Guinea 1992-2001. Med. J. Aust. 2004, 181:687-691.
38. Meier J. Commercially available antivenoms (" hyperimmune sera" , " antivenins" , " antisera" ) for antivenom therapy. Handbook of Clinical Toxicology of Animal Venoms and Poisons 1995, 689-721. CRC Press, Florida. J. Meier, J. White (Eds.).
39. Meyer W.P., Habib A.G., Onayade A.A., Yakubu A., Smith D.C., Nasidi A., Daudu I.J., Warrell D.A., Theakston R.D.G. First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (IPSER) Africa antivenom. Am. J. Trop. Med. Hyg. 1997, 56:291-300.
40. Otero-Patiño R., Cardoso J.L.C., Higashi H.G., Núñez V., Díaz A., Toro M.F., García M.E., Sierra A., García L.F., Moreno A.M., Medina M.C., Castañeda N., Silva-Díaz J.F., Murcia M., Cárdenas S.Y., Dias Da Silva W.D., The Regional Group on Antivenom Therapy Research (REGATHER) A randomized, blinded, comparative trial of one pepsin-digested and two whole IgG antivenoms for Bothrops snake bites in Urabá, Colombia. Am. J. Trop. Med. Hyg. 1998, 58:183-189.
41. Quijada-Mascareñas A., Wüster W. Recent advances in snake venom systematics. Handbook of Venoms and Toxins of Reptiles 2009, 25-64. CRC Press, Boca Raton, FL. S.P. Mackessy (Ed.).
42. Reid H.A. Myoglobinuria and sea-snake-bite poisoning. Br. Med. J. May 6 1961, 1(5235):1284-1289.
43. Rosenberg W., Haines L. Competing designs for phase I clinical trials: a review. Stat. Med. 2002, 21:2757-2770.
44. Saravia P., Rojas E., Arce V., Guevara C., López J.C., Chaves E., Velásquez R., Rojas G., Gutiérrez J.M. Geographic and ontogenetic variability in the venom of the neotropical rattlesnake Crotalus durissus: pathophysiological and therapeutic implications. Rev. Biol. Trop. 2002, 50:337-346.
45. Segura A., Herrera M., González E., Vargas M., Solano G., Gutiérrez J.M., León G. Stability of equine IgG antivenoms obtained by caprylic acid precipitation: towards a liquid formulation stable at tropical room temperature. Toxicon 2009, 53:609-615.
46. Segura A., León G., Su C.Y., Gutiérrez J.M., Burnouf T. Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom. Biologicals 2009, 37:306-312.
47. Sharma S.K., Chappuis F., Jha N., Bovier P.A., Loutan L., Koirala S. Impact of snake bites and determinants of fatal outcomes in southeastern Nepal. Am. J. Trop. Med. Hyg. 2004, 71:234-238.
48. Simpson I.D. A study of the current knowledge base in treating snake bite amongst doctors in the high-risk countries of India and Pakistan: does snake bite treatment training reflect local requirements?. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:1108-1114.
49. Smalligan R., Cole J., Brito N., Laing G.D., Mertz B.L., Manock S., Maudlin J., Quist B., Holland G., Nelson S., Lalloo D.G., Rivadeneira G., Barragan M.E., Dolley D., Eddleston M., Warrell D.A., Theakston R.D.G. Crotaline snake bite in the ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms. Br. Med. J. 2004, 329(7475):1129.
50. Snow R.W., Bronzan R., Roques T., Nyamawi C., Murphy S., Marsh K. The prevalence and morbidity of snake bite and treatment-seeking behaviour among a rural Kenyan population. Ann. Trop. Med. Parasitol. 1994, 88:665-671.
51. Stock R.P., Massougbodji A., Alagón A., Chippaux J.P. Bringing antivenoms to sub-Saharan Africa. Nat. Biotechnol. 2007, 25:173-177.
52. Swaroop S., Grab B. Snakebite mortality in the world. Bull. World Health Organ. 1954, 10:35-76.
53. Theakston R.D.G. Characterization of venoms and standardization of antivenoms. Natural Toxins. Animal, Plant and Microbial 1986, 287-303. Clarendon Press, Oxford. J.B. Harris (Ed.).
54. Theakston R.D.G., Reid H.A. Development of simple standard assay procedures for the characterization of snake venoms. Bull. World Health Organ. 1983, 61:949-956.
55. Theakston R.D.G., Warrell D.A. Crisis in antivenom supply for Africa. Lancet 2000, 356:2104.
56. Theakston R.D.G., Warrell D.A., Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003, 41:541-557.
57. Trape J.F., Pison G., Guyavarch E., Mane Y. High mortality from snakebite in south-eastern Senegal. Trans. R. Soc. Trop. Med. Hyg. 2001, 95:420-423.
58. Visser L.E., Kyei-Faried S., Belcher D.W., Geelhoed D.W., van Leeuwen J.S., van Roosmalen J. Failure of a new antivenom to treat Echis ocellatus snake bite in rural Ghana: the importance of quality surveillance. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:445-450.
59. Wagstaff S.C., Laing G.D., Theakston R.D.G., Papaspyridis C., Harrison R.A. Bioinformatics and multiepitope DNA immunization to design rational snake antivenom. PLoS Med. 2006, 3:e184.
60. Waning B., Kaplan W., King A.C., Lawrence D.A., Leufkensd H.G., Fox M.P. Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bull. World Health Organ. 2009, 87:520-528.
61. Warrell D.A., Williams D.J. Response to comment on: failure of a new antivenom to treat Echis ocellatus snake bite in rural Ghana: the importance of quality surveillance. Trans. R. Soc. Trop. Med. Hyg. 2009, 103:965-966.
62. Warrell D.A. Clinical toxicology of snakebite in Africa and the Middle East/Arabian peninsula. Handbook of Clinical Toxicology of Animal Venoms and Poisons 1995, 433-492. CRC Press, Florida. J. Meier, J. White (Eds.).
63. Warrell D.A. Geographical and intraspecies variation in the clinical manifestations of envenoming by snakes. Venomous Snakes. Ecology, Evolution and Snakebite 1997, 189-203. Clarendon Press, Oxford. R.S. Thorpe, W. Wüster, A. Malhotra (Eds.).
64. Warrell D.A. Unscrupulous marketing of snake bite antivenoms in Africa and Papua new Guinea: choosing the right product- 'What's in a name?'. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:397-399.
65. Williams, D.J., Gutiérrez, J.M., Harrison, R.A., Warrell, D.A., White, J., Winkel, K.D., Gopalakrishnakone, P., An antidote for snake bite: the Global Snake Bite Initiative. Lancet, in press.
66. Williams D.J., Jensen S.D., O'Shea M. Snakebite Management in Cambodia: Towards Improved Prevention, Clinical Treatment and Rehabilitation 2009, Report to WHO/WPRO and Cambodian Ministry of Health, University of Melbourne, 73 pp.
67. World Health Organization Progress in the Characterization of Venoms and Standardization of Antivenoms. WHO Offset Publication 58 1981, WHO, Geneva.
68. World Health Organization Public Health, Innovation and Intellectual Property Rights 2006, World Health Organization, Geneva. http://www.who.int/intellectualproperty/report/en/.
69. World Health Organization Rabies and Envenomings. A Neglected Public Health Issue 2007, World Health Organization, Geneva.
70. World Health Organization International Statistical Classification of Diseases and Related Health Problems, 10th Revision 2007, WHO, Geneva. http://apps.who.int/classifications/apps/icd/icd10online/.
71. World Health Organization WHO Model List of Essential Medicines 2007, WHO, Geneva. http://www.who.int/medicines/publications/essentialmedicines/en/index.html.